- Email: [email protected]
Corrigendum to “Homocysteine enhances apoptosis in human bone marrow stromal cells” [Bone 39 (2006) 582–590]
Bone 40 (2007) 554 – 555 www.elsevier.com/locate/bone
Corrigendum
Corrigendum to “Homocysteine enhances apoptosis in human bone marrow stromal cells” [Bone 39 (2006) 582–590] Duk Jae Kim a , Jung-Min Koh a , Oksun Lee b , Na Jung Kim b , Young-Sun Lee b , Yang Soon Kim b , Joong-Yeol Park a , Ki-Up Lee a , Ghi Su Kim a,⁎ a
Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Poongnap-Dong, Songpa-Gu, Seoul 138-736, Republic of Korea b Asan Institute for Life Sciences, 138-736 Seoul, Korea Available online 13 November 2006
The designation of the groups in Fig. 3 is incorrect. The white dot indicates “Hcy 100 μM,” and the black dot indicates “Control.” The correct figure appears on the following page. In addition, on page 586, in line 2, the figure reference should read “(Fig. 1C)” instead of “(Fig. 1A).”
DOI of original article: 10.1016/j.bone.2006.03.004. ⁎ Corresponding author. Fax: +82 2 3010 6962. E-mail address: [email protected] (G.S. Kim). 8756-3282/$ - see front matter © 2006 Elsevier Inc. All rights reserved. doi:10.1016/j.bone.2006.10.001
Corrigendum
555
Fig. 3. Homocysteine (Hcy) enhances the activity of caspase-9 and caspase-3 but not caspase-8. Activities of specific caspases were measured in HS-5 cells using commercially available assay kit (A–C). After treatment with or without 100 μM of Hcy for indicated times, the enzyme activity was measured as the fluorescence produced by cleavage of substrate by the respective caspase. (D) HS-5 cells were treated with 50 μM of caspase-8 inhibitor (Ac-DEVD-CHO) and caspase-9 inhibitor (LEHD-CHO) 2 h prior to Hcy 100 μM treatment. After 24 h of incubation, the cells were prepared to measure caspase-3 activity. All experiments were repeated three times of triplicate measurements. Shown are the mean (+SD) percentages of the untreated control levels at 0 h. *P < 0.01 vs. untreated control, †P < 0.01 vs. Ac-DEVDCHO-treated control.
Corrigendum
Corrigendum to “Homocysteine enhances apoptosis in human bone marrow stromal cells” [Bone 39 (2006) 582–590] Duk Jae Kim a , Jung-Min Koh a , Oksun Lee b , Na Jung Kim b , Young-Sun Lee b , Yang Soon Kim b , Joong-Yeol Park a , Ki-Up Lee a , Ghi Su Kim a,⁎ a
Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Poongnap-Dong, Songpa-Gu, Seoul 138-736, Republic of Korea b Asan Institute for Life Sciences, 138-736 Seoul, Korea Available online 13 November 2006
The designation of the groups in Fig. 3 is incorrect. The white dot indicates “Hcy 100 μM,” and the black dot indicates “Control.” The correct figure appears on the following page. In addition, on page 586, in line 2, the figure reference should read “(Fig. 1C)” instead of “(Fig. 1A).”
DOI of original article: 10.1016/j.bone.2006.03.004. ⁎ Corresponding author. Fax: +82 2 3010 6962. E-mail address: [email protected] (G.S. Kim). 8756-3282/$ - see front matter © 2006 Elsevier Inc. All rights reserved. doi:10.1016/j.bone.2006.10.001
Corrigendum
555
Fig. 3. Homocysteine (Hcy) enhances the activity of caspase-9 and caspase-3 but not caspase-8. Activities of specific caspases were measured in HS-5 cells using commercially available assay kit (A–C). After treatment with or without 100 μM of Hcy for indicated times, the enzyme activity was measured as the fluorescence produced by cleavage of substrate by the respective caspase. (D) HS-5 cells were treated with 50 μM of caspase-8 inhibitor (Ac-DEVD-CHO) and caspase-9 inhibitor (LEHD-CHO) 2 h prior to Hcy 100 μM treatment. After 24 h of incubation, the cells were prepared to measure caspase-3 activity. All experiments were repeated three times of triplicate measurements. Shown are the mean (+SD) percentages of the untreated control levels at 0 h. *P < 0.01 vs. untreated control, †P < 0.01 vs. Ac-DEVDCHO-treated control.